Harrow Inc (HROW) Stock Price, Quote & News

Company Profile

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract sur...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 615 733 4730

Website: www.harrow.com

Address:

1A Burton Hills Boulevard, Suite 200, Nashville, United States

JFais Nov. 15 at 9:58 PM

$HROW (L) From Weekly Recap

1 · Reply

Finnish_boy Nov. 15 at 5:35 PM

$HROW Finns buying.. i told them.. and holding tight at least 1 year.. huge gains ahead for them and loads of taxes for shitty finnish economy, only country in EU negative GDP. Baum can pump finnish economy to positive.

1 · Reply

Finnish_boy Nov. 15 at 5:24 PM

$HROW I assume VEVYE ASP being stable/little improvement in Q4 (Apollo + ALTO) and starting to grow more rapidly next year by huge coverage win. And if ASP would be down in Q4, i wont sell the stock. ASP will be up hugely in a year.

2 · Reply

Finnish_boy Nov. 15 at 4:57 PM

$HROW Anyways, EPS growth will be big. How big, time will tell. SP anyways skyrocketing in a year. i can tell that.

0 · Reply

Finnish_boy Nov. 15 at 10:53 AM

$HROW I did math and they will hit easily their new guidance.. ImprimisRX stock level issue was the reason they had to lower the guidance. Now, markets dont care the lowering of FY25 guidance because it's so irrelevant. Also, markets dont care what the FY25 total will be bc we live then March and then outlook guidance matter. Markets are forward looking. Very happy now.

1 · Reply

Fullback Nov. 15 at 3:26 AM

$HROW Largest open interest I see on $HROW calls are the Jan 26 $50 Strike

1 · Reply

Finnish_boy Nov. 14 at 11:14 PM

$HROW I hold these stocks at the moment (1st biggest): 1. HROW: going to $100 in H2 next year, 10x potential in 7 years. 2. GOSS: crazy high PoS readout in February. 3. CIFR: more deals this year. 100% gains in a year. 4. PYPD: what a no-brainer stock. Going to double next year. 5. IREN: $100 stock next year. After pullback under $50 again. Stocks i will likely buy in 4 months: TMDX, HITI, SL, GLNG. Especially HITI is so easy money in long-ter, it's so easy when you know the story. It's $10 stock in 2027-28 imho. Now $2.7. I will load that baby before next earnings and not selling before $10. I am ready to make money. Have a nice weekend!

1 · Reply

Finnish_boy Nov. 14 at 4:39 PM

$HROW Agree. Only way to win to load the truck and doing nothing in a year or two.. you will make up 100-200% gains. easy money. ignore VEVYE ASP, California legal stuff, and near-term price action

1 · Reply

stockinvestor102 Nov. 14 at 3:20 PM

$HROW bought more.

0 · Reply

Finnish_boy Nov. 14 at 3:16 PM

$HROW What you think where SP is at the end of 2025? I think more and more people realize how undervalued Harrow is.. more coverage, not anymore so under radar.. SP should double today but SP can go again under $30. Very toxic stock. Those green lines are my buying orders. I want extra shares when SP recovers enough. I dont trust market pricing in case of HROW. Markets are missing this case totally.

1 · Reply

Harrow, Inc. (HROW) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 4:05 PM EST - 5 days ago

Harrow Announces Third Quarter 2025 Financial Results

Nov 5, 2025, 12:31 PM EST - 10 days ago

Harrow Q3 Earnings Preview: This Business Has Eye-Popping Potential

Oct 27, 2025, 7:00 AM EDT - 19 days ago

Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025

Oct 15, 2025, 9:03 PM EDT - 4 weeks ago

Harrow: Positive And Negative Adjustments After Investor Day Offset Each Other

Oct 6, 2025, 7:00 AM EDT - 5 weeks ago

ImprimisRx Announces Leadership Changes

Sep 27, 2025, 12:27 AM EDT - 7 weeks ago

Harrow, Inc. (HROW) Analyst/Investor Day Transcript

Sep 26, 2025, 7:00 AM EDT - 7 weeks ago

Harrow to Acquire Melt Pharmaceuticals

Sep 25, 2025, 4:05 PM EDT - 7 weeks ago

Harrow Launches Harrow Access for All (HAFA)

Sep 15, 2025, 7:00 AM EDT - 2 months ago

Harrow Announces Agenda and Speakers for Investor & Analyst Day

Sep 12, 2025, 10:57 AM EDT - 2 months ago

Harrow: Buy A Blend Of Value And Growth

Sep 9, 2025, 1:11 PM EDT - 2 months ago

Harrow: A Classical GARP Stock

Sep 8, 2025, 5:57 PM EDT - 2 months ago

Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030

Sep 8, 2025, 8:00 AM EDT - 2 months ago

Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030

Aug 14, 2025, 11:09 PM EDT - 3 months ago

Harrow's Ambitious Guidance Puts It In The Proving Ground

Aug 13, 2025, 5:39 PM EDT - 3 months ago

Harrow: Exciting Times In Store

Aug 12, 2025, 2:47 PM EDT - 3 months ago

Harrow, Inc. (HROW) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 4:01 PM EDT - 3 months ago

Harrow Announces Second-Quarter 2025 Financial Results

Aug 6, 2025, 7:00 AM EDT - 3 months ago

Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference

Jul 29, 2025, 7:00 AM EDT - 3 months ago

Harrow To Report Second Quarter 2025 Financial Results After Market Close on August 11, 2025

Jul 17, 2025, 7:00 AM EDT - 4 months ago

Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States

Jul 17, 2025, 7:00 AM EDT - 4 months ago

Samsung Bioepis Enters into a Partnership with Harrow for Commercialization of Ophthalmology Biosimilars Portfolio in the United States

Jul 15, 2025, 10:38 AM EDT - 4 months ago

HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm

Jul 11, 2025, 5:47 PM EDT - 4 months ago

Harrow's Internal $100 Price Target Is Ambitious, But New Bloomberg Data Backs It Up

Jul 9, 2025, 2:52 PM EDT - 4 months ago

Harrow: Immense Upside Potential

Jun 18, 2025, 7:00 AM EDT - 5 months ago

Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

Jun 13, 2025, 8:30 AM EDT - 5 months ago

I Am Swimming In Dividends With +7% Yields

UMH

Jun 9, 2025, 7:00 AM EDT - 5 months ago

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

May 28, 2025, 3:20 PM EDT - 6 months ago

Harrow: Epic Growth & Operating Leverage On Full Display

May 14, 2025, 7:00 AM EDT - 6 months ago

Harrow to Present at Two Investor Conferences in May

May 10, 2025, 6:17 PM EDT - 6 months ago

Harrow, Inc. (HROW) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:01 PM EDT - 6 months ago

Harrow Announces First-Quarter 2025 Financial Results

May 5, 2025, 7:00 AM EDT - 6 months ago

Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025

Apr 24, 2025, 10:00 AM EDT - 7 months ago

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC.

Apr 10, 2025, 7:00 AM EDT - 7 months ago

Harrow Expands VEVYE® Access for All Program to ImprimisRx's Klarity-C Patients

Mar 29, 2025, 4:30 PM EDT - 8 months ago

Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)

Mar 28, 2025, 2:00 PM EDT - 8 months ago

Harrow, Inc. (HROW) Q4 2024 Earnings Conference Call

Mar 28, 2025, 1:39 PM EDT - 8 months ago

Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp

Mar 27, 2025, 4:01 PM EDT - 8 months ago

Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results

Mar 27, 2025, 10:45 AM EDT - 8 months ago

Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025

Mar 24, 2025, 7:00 AM EDT - 8 months ago

Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL

Mar 17, 2025, 4:01 PM EDT - 8 months ago

Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance

Mar 17, 2025, 7:00 AM EDT - 8 months ago

Harrow Launches VEVYE® Access for All

Mar 11, 2025, 7:00 AM EDT - 8 months ago

Harrow Executes Five-Year Strategic Supply and Development Agreement for TRIESENCE®

Mar 3, 2025, 7:15 AM EST - 9 months ago

Harrow to Report Fourth Quarter and Year-End 2024 Financial Results After Market Close on March 17, 2025

Mar 1, 2025, 8:50 AM EST - 9 months ago

Smallcap Eyecare Pharma Company Harrow Health Has Two Major Catalysts For 2025

Jan 27, 2025, 7:30 AM EST - 10 months ago

Harrow Partners with Cencora to Launch “Harrow Cares” Program, Making IHEEZO® and TRIESENCE® More Accessible and Affordable for Retina Specialists and Their Patients

COR

JFais Nov. 15 at 9:58 PM

$HROW (L) From Weekly Recap

1 · Reply

Finnish_boy Nov. 15 at 5:35 PM

1 · Reply

Finnish_boy Nov. 15 at 5:24 PM

2 · Reply

Finnish_boy Nov. 15 at 4:57 PM

$HROW Anyways, EPS growth will be big. How big, time will tell. SP anyways skyrocketing in a year. i can tell that.

0 · Reply

Finnish_boy Nov. 15 at 10:53 AM

1 · Reply

Fullback Nov. 15 at 3:26 AM

$HROW Largest open interest I see on $HROW calls are the Jan 26 $50 Strike

1 · Reply

Finnish_boy Nov. 14 at 11:14 PM

1 · Reply

Finnish_boy Nov. 14 at 4:39 PM

$HROW Agree. Only way to win to load the truck and doing nothing in a year or two.. you will make up 100-200% gains. easy money. ignore VEVYE ASP, California legal stuff, and near-term price action

1 · Reply

stockinvestor102 Nov. 14 at 3:20 PM

$HROW bought more.

0 · Reply

Finnish_boy Nov. 14 at 3:16 PM

1 · Reply

Finnish_boy Nov. 14 at 3:12 PM

$HROW Lets cook

0 · Reply

JFais Nov. 14 at 2:38 PM

$HROW- from upcoming Q3 portfolio update

0 · Reply

Finnish_boy Nov. 14 at 10:16 AM

$HROW Btw HROW>HIMS. i knew this is going to happen.

1 · Reply

Finnish_boy Nov. 14 at 9:53 AM

$HROW

0 · Reply

Finnish_boy Nov. 14 at 9:50 AM

$HROW Vevye FDA approval was before they bought Xiidra. I think they had chance to buy VEVYE. They made huge mistake. If there was a real offer that FTC blocked, that would be public info. But ofc can be that there was some communication that you cant buy all drugs when their plan was to buy Xiidra also. But yea we never know the truth likely. But they could have buy VEVYE and withdraw the Xiidra acquistion bc it wasnt closed yet.

0 · Reply

HROW200 Nov. 14 at 5:00 AM

$HROW Historically, cataract surgery patients were given three eyedrops to be used for one month. ImprimisRx compounded the drugs into one bottle. Now Harrow is trying to get clinicians to go dropless. At the time of cataract surgery, patients will receive injections of moxifloxacin and Triesence. No drops post-op will be required.

1 · Reply

Fullback Nov. 14 at 2:59 AM

$HROW I feel like there is a legit path to $450M in 2026. Where am I too optimistic?

4 · Reply

Finnish_boy Nov. 14 at 1:19 AM

$HROW Main reason is likely that the combo is much better than Xiidra. And great R/R project when both Xiidra and Miebo work alone (no need for phase1). Also Xiidra patent is expiring in future. But yea, ignore these posts, not any impact. TRYPTYT is bigger risk for VEVYE than this project.

0 · Reply

Finnish_boy Nov. 14 at 1:11 AM

$HROW Also, is this the strategy to avoid potential issues with Miebo pricing when it's OTC drug elsewhere? I think no. I think this is probably the strategy for expiring of Xiidra patent. And was this the plan when BLCO acquired Xiidra? Why they didnt acquire VEVYE (any issues with that)? And what will happen to Miebo sales if this hits the market. This would be direct competitor of Miebo. Xiidra will go to generics in future anyways. Also BLCO CEO has never mentioned VEVYE. I dont trust them. CEO told also that Miebo performance was great in Q3 considering new drug launch of TRYPTYR lol. Vevye skyrockets in any case and be market leader. We won the game already.

1 · Reply

Finnish_boy Nov. 14 at 12:41 AM

$HROW I dont post this topic for finnish community on twitter because when you think more about of this potential arrival of "Xiidra+Miebo" in 2029, it really doesnt matter much. VEVYE ramp up is ready then, happy doctors/patients using VEVYE (high refill rates, no need to change the product), market leader, and potential issues with "Xiidra+Miebo". No news for me.

0 · Reply

Finnish_boy Nov. 13 at 11:55 PM

$HROW This sounds like VEVYE haha. This can be great drop also but not sure about efficacy and tolerability vs VEVYE.. but yea, luckily 4 years away. Vevye is already then massive gorilla with tons of patients that like vevye and do refills. but i posted this because kind of interesting thing, not a threat our stock.

1 · Reply

Finnish_boy Nov. 13 at 11:44 PM

$HROW Well, VEVYE works also evaporative dry eye. Maybe VEVYE more comfortable and more efficient --> BLCO guided VEVYE 1B drug.. thanks.

0 · Reply

Market Cap	1.51B
Revenue (ttm)	199.61M
Net Income (ttm)	-17.48M
EPS (ttm)	N/A
PE Ratio	86.11
Forward PE	55.18
Profit Margin	-8.76%
Debt to Equity Ratio	0.78

Volume	771,500
Avg Vol	810,318
Day's Range	N/A - N/A
Shares Out	37.04M
Stochastic %K	92%
Beta	0.19
Analysts	Strong Sell
Price Target	$71.43